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Nanotechnology is a current trend in cancer research, more specifically, in cancer 
diagnosis and therapy. In one hand, nanostructures are useful tools in cell proliferation 
and tumor marker assays to detect the presence and/or activity of tumor cells at 
relatively low percentages in biological fluids and/or tissues. On the second, modern 
therapies are based on drug delivery systems involving the use of nano-carriers, which 
decrease the side effects to patients and provide a higher effectiveness in the treatment 
of the disease. 
Tumor makers are molecules used as indicators of the presence of cancer, the response 
to the therapy or the development of the disease. An important group of these markers is 
constituted by glycoproteins, such as prostate specific antigen (PSA), α-fetoprotein 
(AFP), human chorionic gonadotropin (hCG) and carcinoembryonic antigen (CEA). 
Other useful markers are the mucinous glycoproteins cancer antigen 125 (CA 125), 
cancer antigen (CA 15-3) and carbohydrate antigen 19-9 (CA 19-9). These proteins are 
mainly determined by using immunological mehods, which have traditionally involved 
the use of enzymes or fluorophores as labels. Nanoparticles (NPs) can be used in tumor 
marker assays as labels, nanoscaffolds and separation media. Carbon nanotubes, 
quantum dots, and noble metal, organic polymer, silica and magnetic NPs are the main 
nanomaterials that have shown their usefulness for these purposes up to date. Generally, 
the use of nanotechnology in tumor marker assays has provided them with shorter 
analysis times and higher sensitivity compared to the conventional methods. These 
assays can be miniaturized using microarray or microfluidic systems and allow the 
individual or multiplexed determination of tumor markers using direct, competitive or 
sandwich schemes. 
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